MicroRNA-155 Tissue Expression in Patients with Breast Cancer at Dr Haji Adam Malik Hospital, Medan
Abstract
Background: MicroRNA (miRNA) is noncoding-RNA that comprises 18-22 nucleotides. miRNA binds its gene targets in the 3'-untranslated region (3'-UTR), causing direct degradation of mRNA and repressed translation of RNA. MicroRNA regulates various biological processes, including cell proliferation, apoptosis, cell growth, cell differentiation, and metabolism. Various changes have been identified miRNA expression in different types of cancers. This study aimed to describe the expression of miR-155 in patients with breast cancer tissue in Haji Adam Malik Hospital in Medan.
Subjects and Method: This was a descriptive study. A total sample was 64 paraffin tissue blocks was taken from female patients with breast cancer at the surgical oncology unit, Haji Adam Malik Hospital in 2013-2014. RNA sample were isolated and checked using a spectrophotometer followed by cDNA synthesis. Then this sample was analyzed for miR-155 expression by using Real Time qPCR. Histopathological grade data were obtained from the medical record.
Results: The miR-155 expression in the breast cancer patients is higher than that in the UniSp6 RNA Spike-in (internal controls). miR-155 expression was 29.64, 28.44, 29.22, in grade-I, grade-II, grade-III breast cancer, respectively. UniSp6 RNA Spike-in was 22.30, 22.89, 23.10, respectively in the control groups. Thus, increased of miR-155 expression was the highest in grade I breast cancer patients.
Conclusion: Increased miR-155 expression can be used as a biomarker for early diagnosis and prognosis of breast cancer.
Keywords: miRNA, miR-155, breast cancer.
Correspondence: Henny Erina Saurmauli Ompusunggu. Department of Cellular and Molecular Biology, Faculty of Medicine, HKBP Nommensen University, Medan. Email: ompusunggu.henny@gmail.com
Indonesian Journal of Medicine (2016), 1(1): 20-25
https://doi.org/10.26911/theijmed.2016.01.01.03
References
Anderson. (2002). Progesterone receptors animal models and cell signaling in breast cancer: The role of estrogen and progesterone receptors in human mammary development and tumor genesis. Breast Cancer Res; 4: 197-201.
Dağlar G, Yuksek YN, Gozalan AU, Tutuncu T, Gungor Y, and Kama NA. (2010).
The prognostic Value of Histopatological Grade in the Outcome of Patients with Invasive Breast Cancer. Turk J Med Sci; 40 (1): 7-15.
Hauptman N and Glavac D. (2013). MicroRNAs and Long Non coding RNAs: Prospects in Diagnostics and Therapy of Cancer. Radiol Oncol, 47(4): 311-318.
Health Department. (2009). Prevention of Cervical Cancer and Breast Cancer.http://www.pppl.depkes.go.id/asset/download/bukusaku_kanker.pdf. April 10, 2014.
Huntzinger E and Izaurralde E. (2011). Gene Silencing by MicroRNAs: Contributions of Translational Repression and mRNA Decay. Nature, 12: 99-110.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R. (2005). Deregulation Micro RNA Gene Expression in Human Breast Cancer. Cancer Res, 65 (16): 7065-7070.
Kumar V, Cotran RS, and Robbins SL. (2007). Textbook of Pathology Robbins. Female genital system and breasts: Breast. EGC. Jakarta.
Lu Z, Ye Y, Jiao D, Qiao J, Cui S, and Liu Z. (2012). miR-155 and miR-31 are differentially Expressed in Breast Cancer Patients and are correlated with the estrogen receptor and progesterone receptor status. Oncology Letters, 4: 1027-1032.
Mar-Aguilar F, Mendoza Ram'ırez JA, Malag'on Santiago I, Espino-Silva PK, Santuario Facio SK. (2013). Serum circulating MicroRNA profiling for identification of potential breast cancer biomarkers. Disease Markers, 34: 163-169.
Mattiske S, Suetani RJ, Neilsen PM, Callen DF. (2012). Cancer Epidemiol Biomarkers Prevention: The Oncogenic Role of miR-155 in Breast Cancer. American Association for Cancer Research. cebp.aacrjournals. org. Sept 4th, 2013.
Miki Y, Swensen J, Shattuck Eidens D, Futreal PA, Harshman K. (1994). A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science, 266: 66-71.
Oakley KL and Going JJ. (1995). Slice Specimen Radiography of Cancer in Breast Conserving excisions. JClin Pathol, 48: 1028-1030.
Ostad SN and Parsa M. (2011). Breast Cancer from Molecular Point of View:
Pathogenesis and Biomarkers. Chapter 6. Faculty of Pharmacy, Tehran University of Medical Sciences. Tehran. http://cdn.intechopen.com/pdfs-wm/24879.pdf. Apr 10th, 2014.
Rodriguez A, Griffiths Jones S, Ashurst JL, Bradley A. (2004). Identification of mammalian host MicroRNA genes and transcription units. Genome Res, 14: 1902-1910.
Szafranska AE, Davison TS, Shingara J, Doleshal M., Riggenbach JA. (2008). Accurate Molecular characterization of Formalin Fixed, Paraffin Embedded Tissues by MicroRNA Expression Profiling. JMD, 10 (5): 415-423.
Tavassoli FA and Devilee P. (2003). Pathology and Genetics: Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours; 5. IARC Press. Lyon.
Tryggvadottir L, Olafsdottir EJ, Gudlaugsdottir S, Thorlacius S, Jon G. (2003).
BRCA2 mutation carriers, reproducetive factors and breast cancerRisk. Breast Cancer Res; 5: R121-r128.
Valencia-Sanchez MAV, Liu J, Hannon GJ, Parker R. (2006). Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev; 20: 515-524.
Volinia S, Calin GA, Liu C, Ambs S, Cimmino A. (2006). A MicroRNA expression signature of human solid tumors defines cancer gene targets. PNAS, 103 (7): 2257-2261.
Wang F, Zheng Zhiguo Z, Guo J, and Ding X. (2010). Correlation and quantitation of MicroRNA aberrant expression in tissues and sera from Patients with breast tumors. Gynecol Oncol doi;10.1016 /j.ygyno. 2010.07.021: 1-8.
WHO. (2013). Breast cancer: prevention and control. http://www.who.int/cancer/detection/breastcancer/en/. 24th Nov, 2013.
Wrensch M, Chew T, G Farren, Barlow J, Belli F. (2003). Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res; 5: R88-R102.
Zhao SY, Wu Q, Gao F, Zhang CB, and Yang XW. (2012). Serum MicroRNA-155 as a potential biomarker for breast cancer screening. Chin Sci Bull, 57: 3466-3468.
